The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).
 
Amanda Psyrri
Honoraria - Bayer; Bristol-Myers Squibb; Genesis Pharmaceuticals; Merck Serono; MSD Oncology; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pfizer
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Roche
 
Niki Gavrielatou
No Relationships to Disclose
 
Aris Spathis
No Relationships to Disclose
 
Maria Anastasiou
No Relationships to Disclose
 
Ekaterina Fortis
No Relationships to Disclose
 
Maria Gkotzamanidou
No Relationships to Disclose
 
Athina Kladi-Skandali
No Relationships to Disclose
 
Evgenia Kousidou
No Relationships to Disclose
 
Panagiota Economopoulou
No Relationships to Disclose
 
Ioannis Kotsantis
No Relationships to Disclose
 
Sylvie Rusakiewicz
No Relationships to Disclose
 
Elena Mihal Vagia
No Relationships to Disclose
 
Ioannis Panayiotides
No Relationships to Disclose
 
George Coukos
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche/Genentech
Speakers' Bureau - Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geneos (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); NextCure (Inst); Roche (Inst); Sanofi/Aventis (Inst)
Patents, Royalties, Other Intellectual Property - George Coukos has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy. George Coukos receives royalties from the University of Pennsylvania (Inst)
 
Periklis Foukas
No Relationships to Disclose